Ferring Pharmaceuticals to Present New Reproductive Medicine Data at ASRM 2021 Scientific Congress & Expo
PARSIPPANY, N.J. , October 14 /Businesswire/ - Ferring Pharmaceuticals (US) today announced that it will be presenting four company-sponsored abstracts at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo taking place October 17-20 in Baltimore, MD.
Ferring will be sharing an oral presentation on new findings from a clinical study observing treatment outcomes of women who were treated with HP-HMG for ovarian stimulation and luteal support with a recently FDA-approved novel progesterone vaginal system (PVS). Additionally, a sub analysis of data from the formerly published MEGASET-HR trial, will be featured in an oral presentation. The sub-analysis evaluates the impact of gonadotropin used for stimulation on early pregnancy loss in predicted high responder patients.
The remaining data to be presented includes one poster describing the utilization of different infertility treatments based upon patient age, observed efficacy and geodemographic data, and the final poster is a Health Economics and Outcomes Research (HEOR) assessment of the cost difference between treatment groups utilizing either highly purified human menopausal gonadotropin (HP-hMG) or recombinant follicle stimulating hormone (rFSH) based on the MEGASET-HR trial outcomes.
“We look forward to sharing data at this year’s ASRM congress, where leaders will gather to present innovative research dedicated to the advancement of science and to reimagine the practice of reproductive medicine inclusive for all aspiring parents,” says Patrick Heiser, Associate Vice President, Clinical Development at Ferring Pharmaceuticals. “Ferring’s continued leadership in reproductive medicine and maternal health, further underscores our commitment to researching life-changing medicines for every person looking to build their families.”
The details of all Ferring abstracts presented at the meeting are as follows:
Oral (O-61):
Title: Evaluation of Possible Factors Contributing to Early Pregnancy Loss in Predicted High-Responders: MENOPUR in GNRH (Gonadotropin Releasing Hormone) Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) Trial Analysis
Date and Time: Monday, October 18, 2021; 10:45 AM – 11:00 AM
Oral (O-18):
Title: Treatment Outcomes After Highly Purified Human Menopausal Gonadotropin (HP-HMG) Ovarian Stimulation and Luteal Support with a Novel Progesterone Vaginal System (PVS): SARA Trial Analysis
Date and Time: Monday, October 18, 2021; 12:00 PM – 12:15 PM
Poster (P-152):
Title: Characterization of the US Infertility Patient Journey: Evaluation of Real-World Data from US Assisted Reproductive Technology (ART) Centers
Date and Time: Tuesday, October 19, 2021; 6:30 AM – 7:45 AM
Poster (P-377):
Title: Cost Comparison of Highly Purified Human Menopausal Gonadotropin (HP-HMG) Versus Recombinant Follicle-stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US High-Responder Patients Based on the MEGASET-HR Trial
Date and Time: Tuesday, October 19, 2021; 6:30 AM – 7:45 AM
For more information on the abstracts, visit asrmcongress.org/
Menopur® Indication
Menopur (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in ovulatory patients participating in an Assisted Reproductive Technology (ART) program.
Important Safety Information
Menopur is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman.
Menopur should only be used by physicians who are thoroughly familiar with infertility problems. Menopur is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with Menopur. There have been infrequent reports of ovarian neoplasms with Menopur. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with Menopur.
The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.
Please see here for full Prescribing Information.
MILPROSA™ Indication
MILPROSA (progesterone) vaginal system is indicated to support embryo implantation and early pregnancy (up to 10 weeks post-embryo transfer) by supplementation of corpus luteal function as part of an ART treatment program for infertile women up to and including 34 years of age.
Important Safety Information
MILPROSA is contraindicated in women with known sensitivity to progesterone or any of the ingredients of MILPROSA, undiagnosed vaginal bleeding, severe hepatic impairment or disease, known or suspected malignancy of the breast, or active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
The most common adverse reactions reported at ≥2% with MILPROSA were headache, vaginal discharge, nausea, breast tenderness, post procedural discomfort, abdominal distension, abdominal pain, pelvic pain, and constipation.
Please see here for full Prescribing Information.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and orthopaedics. For more information, call 1-888-FERRING + (1-888-337-7464); visit http://www.ferringusa.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005128/en/
